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ciated with the lower baseline serum HBV DNA levels, HBV DNA
negativity at week 24 and undetectable serum YMDD mutation
at week 12 compared with non-response. Early treatment with
adefovir dipivoxil for the patients with YMDD mutation who had
virological breakthrough and without biochemical breakthrough
can reach for better curative effect.
PP-115 Hepatitis B vaccination of chronic HBV infected
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Background: Over time, the levels of HBsAg in some chronic HBV
infected individuals declines and is not detectable in the serum.
The purpose of this study was to assess the efﬁcacy of HBV
vaccine in subjects who lost their HBsAg with not seroconverssion
to anti-HBs.
Methods: From April 1993 to December 2007, among 1603 chronic
HBV infected individuals, 34 subjects (22 males, 12 females) be-
came HBsAg negative with no detectable anti-HBs and HBV DNA
in their sera. They received HBV vaccine at 0, 1 and 6 months
(case group). Fifty-two subjects (30 males, 22 females) who were
negative to HBsAg, anti-HBs and anti-HBc received HBV vaccine
like the above schedule (control group). Anti-HBs was assessed
one month of the last dose in these two groups.
Result: The mean age of the case group was 38±12.7 and the
control group was 33.4±8.6 years (p=0.07). The distribution of
sexes between these two groups were equal (p=0.652). The mean
year of follow-up for the case group was 7.6±4.5 years. Anti-HBs
levels ≥10 IU/l was developed in 8 (23.5%) subjects in the case
group and in 45 (86.5%) of the control group (p=0.0001). The
mean anti-HBs levels in the case group was 68±32.66 and in the
control group was 344.6±38.9 IU/l (p=0.00001).
Conclusion: The results show that nearly 24% of chronic HBsAg
positive subjects, who lost their HBsAg responded to hepatitis B
vaccine and the remaining cases need to be followed for occult
HBV infection.
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Background & Aim: Hepatitis B virus (HBV) infection with unde-
tectable levels of hepatitis B surface antigen (HBsAg) is called an
occult infection, which although has been described among sub-
jects with chronic hepatitis C liver disease in the western world,
it’s prevalence and clinical signiﬁcance are still ambiguous in the
Indian subcontinent.
Methods: We investigated HBV-DNA PCR in serum samples of 260
HBsAg negative subjects with chronic HCV-related liver disease,
and 70 apparently healthy volunteers negative for HBsAg and
anti-HCV as control.
Results: Serum samples found positive by at least two indepen-
dent PCR assays were considered HBV DNA positive. HBV-DNA
was detected among 19 HCV-related chronic liver disease (CLD)
patients (7.3%), which was higher (p=0.2) as compared with
the control volunteers (4.3%). It was more frequent (37.5%) in
24 anti- HBs negative/anti-HBc positive patients than in 180
anti-HBs/anti-HBc positive (5%, p<0.05). HCV RNA by qualitative
PCR was signiﬁcantly (p<0.001) higher in occult HBV compare to
non-occult. HCV genotype 1b was predominantly associated with
occult HBV (73%), especially among subjects with hepatocellu-
lar carcinoma (HCC) (p<0.05) as compared to non-occult HBV
cases. Though not signiﬁcant, frequency of occult HBV infection
was higher than healthy controls and HCV 1b genotype was
signiﬁcantly associated in patients with HCC.
Conclusion: This study suggests that in all HBV-endemic areas,
the possibility of occult HBV in patients with HCV should be
considered and HBV-DNA should be performed.
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Objective: To observe the efﬁciency of Thymosin-α1 treatment
in patients with chronic hepatitis B.
Methods: Fifty-six HBeAg-negative and sixty-two HBeAg-positive
patients were randomly divided two groups, received Thymosin-
α1 or Interferon alpha for six months respectively.
Results: At the end of treatment, complete response (CR) oc-
curred in 8 of 26 and 9 of 29 in T-α1 group and in 14 of 30 and
15 of 33 in IFN-α group in HBeAg-negative and HBeAg-positive
patients respectively (p>0.05). After a 6-month follow-up pe-
riod, a CR was observed in 11 of 26 HBeAg-negative and 14 of
29 HBeAg-positive in T-α1 group and in 7 of 30 HBeAg-negative
and 9 of 33 HBeAg-positive patients in IFN-α group (p>0.05).
Compared with the results observed in untreated patients, the
rate of CR was signiﬁcantly higher in IFN-α group at the end of
therapy (p<0.001) and in T-α1 group at the end of follow-up
(p<0.001). Ten of the 12 T-α1 responders experienced sustained
non-detectable HBVDNA after the 6-month treatment period.
Six of the 14 T-α1 non-responders showed delayed response of
non-detectable HBVDNA during the follow-up period. In HBeAg-
positive patients, it is 87.5% and 53.8%. However, the data were
50% and 0%, 59.1% and 0% in IFN-α group, respectively. The rate of
delayed response was signiﬁcantly higher in T-α1 group (p=0.010)
and the rate of ﬂare was higher in IFN-α group (p>0.05) during
the follow-up period.
Conclusion: A 6-months course of T-α1 therapy is effective in CHB
patients with a gradual and more sustained ALT normalization
and HBVDNA loss.
PP-118 Adefovir genotypic resistance in chronic hepatitis
B patients with virological breakthrough during
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Objectives: To investigate the genotypic resistance proﬁles in
chronic hepatitis B patients who underwent virological break-
through during adefovire treatment.
Methods: Serum samples and clinical data were collected from
adefovir treated patients (10mg/d) who underwent virological
breakthrough (HBV DNA increase 1log10 copies/ml from the
Nadir). Adefovir genotypic resistance was detected with PCR
product pyrosequencing. HBV genotypes were identiﬁed by phy-
logenetic tree analysis of PCR product di-deoxy sequencing
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results. Correlation between adefovir resistance and clinical
factors were analyzed.
Results: Totally 106 patients were tested and 45 patients (42.5%)
were adefovir resistance (table 1). There were no statistical
differences in the rising level of HBV DNA (P>0.05) and biochem-
ical breakthrough rates (P>0.05) between patients with single
mutant and combination mutants. But patients with rtA181T
mutant had lower rising level of HBV DNA (P=0.014) and higher
rate of biochemical breakthrough (P=0.023) than resistance
patients without rtA181T mutant. There was no statistical dif-
ference in resistance rate between genotype B and C patients
(P>0.05). Adefovir resistance patients are more common in
lamivudine refractory patients than in nucleoside-naïve patients
(P=0.010).
Table 1. Adefovir resistance in tested virological breakthrough patients
Mutations Cases
rtA181T 13
rtA181V 9
rtN236T 3
rtA181V/T 1
rtA181T+rtN236T 9
rtA181V+rtN236T 8
rtA181V/T+rtN236T 2
Total 45
Conclusion: RtA181T mutant may decrease the HBV DNA rising
level, but increase the possibility of biochemical breakthrough.
In adefovir treated patients underwent virological breakthrough,
adefovir resistances are more common in lamivudine refractory
patients than in nucleoside-naïve patients.
PP-119 One case report of HBV infection with HBsAg
mutation
Xiaoning Zhang*, Wenzheng Wang, Chunyan Liu.
China is a high endemic region of HBV infection and the preva-
lence of HBsAg carriers is ∼10%. As a serum marker, HBsAg is
of predominant importance for diagnosis of HBV infection. We
reported on rare case of HBV infection with negative serum
HBsAg.
The reported case was a 17 years old female student. HBV serum
marker assay 6 month ago showed positive for only HBeAg and
anti-HBc in local town hospital. Conﬁrmative test showed same
results in our hospital with different ELISA and Colloidal Gold
Kits. For exclusion of false negative results of HBsAg caused by
Hook effect, patient serum were diluted in 1:10, 1:20, 1:100 and
1:1000 for detection and results also showed negative for HBsAg.
Negative results were also get when serum samples were under-
went acid dissociation before detection and possible affection
of HBsAg-anti-HBs immune complexes was excluded. The patient
was negative for rheumatoid factor, anti-HCV and anti-HDV. The
quantitive detection of HBsAg showed 0.12 ng/ml (0.00-0.16)
and HBV DNA level was 7.2×104 copies/ml (PCR assay, Cangzhou
central hospital).
Discussion: Repeated detection showed HBV infection in this HB-
sAg negative patient and HBsAg mutation might be the cause of
the false negative result. HBV management faces the new chal-
lenge of HBV genome mutation. α- determinant group of HBsAg is
conserved in different serotype HBV and with speciﬁc conforma-
tion. α- determinant group is the epitope of HBsAg for binding of
anti-HBs and amino acid changes in this region might cause the
changes of conformation thus affecting the antigenicity of HBsAg
by hinding the combination of HBsAg and anti-HBs. This is also
one cause of false negative detection of HBsAg. Different HBsAg
detection kits may use different monoclonal antibodies to HBsAg
and may also cause the discrepancy of HBsAg detection. Many
mutations may appear in HBsAg region and 50∼70% muations may
decrease the binding of HBsAg to anti-HBs monoclonal antibodies
in different levels. Partial muations may signiﬁcantly change the
conformation and antigenicity of HBsAg. Lack of quick assays
for mutant HBsAg and the unconsciousness of the possible risk
of this kind mutation hinder the prompt diagnosis of this kind
patients. In blood donation, this may put high risk in recipients.
So selection HBsAg detection kits with high sensitivity to mutant
HBsAg is of vital important in decrease the misdetection of
mutant HBsAg. From this case, we can also conclude that HBsAg
detection alone as the screening for blood donators may bring
the high risk of blood sample contamination. More effort should
be put on the development of HBsAg detection kit which is more
sensitive in recognizing and bingding mutant HBsAg. And other
screening assays may be considered in decreasing the risk of
blood contamination.
PP-120 Viral hepatitis in Tajikistan
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Viral hepatitis is a major public health problem in all parts of
the world. Infections with hepatitis B are of particular concern
since such infection in some individuals can lead to chronic liver
disease, cirrhosis of the liver, and hepatocellular carcinoma.Two-
thirds of the subjects younger than 20 years old had been
infected with hepatitis A, 56.7% of the 77 children under 5 years
old were positive for at least one hepatitis B virus marker, and
38.2% of individuals aged 5-19 years demonstrated seropositivity
for hepatitis B virus. 39% of adults from the general population
had at least one marker for hepatitis B, 8.9% of pregnant women
were seropositive for hepatitis B surface antigen, and 61.6% of
the infants aged 0-3 years living in orphanages had at least one
marker for hepatitis B. Hepatitis C is circulating in the country.
Prevention measures must include hepatitis B immunization of
infants, with an appropriately targeted immunization strategy
determined through further epidemiological studies.
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Aim: to evaluate the necroinﬂamatory index (HAI) with the Ishak
and Metavir systems and its relationshipship with the demograph-
ical, virusological, biochemical parameters and ﬁbrosis.
Methods: We studied 242 naïve patients admitted in 2003-2006
for chronic hepatitis C, diagnosed according to clinical, biological
and morphological criteria.
Results: Irrespective of the scoring system used, most patients
had mild and moderate hepatitis lesions, with a concordance
between the results of the two examinations existing throughout
the entire group (p=0.000).
The mean age of the patients increased gradually alongside the
worsening of the hepatitis lesions, with both scoring systems,
without any changes of the sex ratio. There were no signiﬁcant
associations between the viral load and the necroinﬂamatory
activity.
We found signiﬁcant associations between the necroinﬂamatory
degrees and the ﬁbrosis stages in both scoring systems (p=0.000).
The patients presenting with hepatocytolysis had more severe
hepatitis lesions, expressed through a higher mean HAI level and
a mean ﬁbrosis index than that in the patients with normal AST
or ALT, although signiﬁcant differences were only obtained for
AST (p=0.011).
Conclusions: 1. From the point of view of the necroinﬂamatory
activity we found a predominance of the mild and moderate
